Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Semaglutide vs Tirzepatide

Q: What is the difference between Semaglutide and Tirzepatide?

Semaglutide is a GLP-1 compound (Subcutaneous route) - Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects. Tirzepatide is a GLP-1 compound (Subcutaneous route) - Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

Q: Which has a longer half-life, Semaglutide or Tirzepatide?

Semaglutide has the longest published plasma half-life (~6.9 days (165 h)), compared with Tirzepatide (~5.0 days (120 h)).

Q: How often is each compound dosed in the research literature?

Semaglutide: once weekly at a published dose range of 0.25–2.4 mg; Tirzepatide: once weekly at a published dose range of 2.5–15 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Semaglutide and Tirzepatide for research use?

Yes - Semaglutide, Tirzepatide are available from New-U Research Compounds as lab-verified (>99% HPLC) compounds.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

GLP1-RC-SM

Semaglutide

GLP-1R agonist

GLP-1R

GLP1-RC-TZ

Tirzepatide

Dual receptor agonist

GLP-1R · GIPR

Key research differences

Semaglutide Tirzepatide Receptor profile GLP-1R GLP-1R · GIPR Development status Approved therapeutic molecule Approved therapeutic molecule Published half-life ~6.9 days (165 h) ~5.0 days (120 h) Research distinction Selective GLP-1R agonism Dual incretin agonism

Published research parameters

Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Tirzepatide Mounjaro, Zepbound View Tirzepatide → Receptor profile GLP-1R GLP-1R · GIPR Class GLP-1R agonist Dual receptor agonist Plasma half-life ~6.9 days (165 h) ~5.0 days (120 h) Time to Cmax 24 h 36 h Development status Approved therapeutic molecule Approved therapeutic molecule Study context Regulatory label PK Regulatory label PK Primary publications FDA Wegovy USPI — half-life ~1 week (165 h) (2024) FDA Mounjaro USPI — half-life ~5 days (120 h) (2024) Summary Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects. Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

View published study parameters

Semaglutide Ozempic, Wegovy, Rybelsus View Semaglutide → Tirzepatide Mounjaro, Zepbound View Tirzepatide → Route in published studies Subcutaneous Subcutaneous Published study interval Once weekly Once weekly Published dose range 0.25–2.4 mg 2.5–15 mg Published study regimen 0.25 → 0.5 → 1 → 1.7 → 2.4 mg 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg

Source references

FDA Wegovy USPI — half-life ~1 week (165 h)

FDA prescribing information · 2024

FDA Wegovy USPI — half-life ~1 week (165 h) (2024)

STEP 1 trial — NEJM 384:989 (titration schedule)

New England Journal of Medicine · 2021

STEP 1 trial — NEJM 384:989 (titration schedule) (2021)

Hall S et al.

Clinical Pharmacokinetics · 2018

Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)

FDA Mounjaro USPI — half-life ~5 days (120 h)

FDA prescribing information · 2024

FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)

SURPASS-2 trial — NEJM 385:503

New England Journal of Medicine · 2021

SURPASS-2 trial — NEJM 385:503 (2021)

Urva S et al.

Clinical Pharmacokinetics · 2022

Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)

Frequently asked questions

What is the difference between Semaglutide and Tirzepatide?

Which has a longer half-life, Semaglutide or Tirzepatide?

How often is each compound dosed in the research literature?

Can you buy Semaglutide and Tirzepatide for research use?

Continue researching

Research guides, current certificates and related research for Semaglutide and Tirzepatide. Research use only.

Research guide Semaglutide research guide Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a… Read the guide →

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Analytical evidence View the Semaglutide COA Current batch purity and identity testing, 2025-04-30. View the COA →

Analytical evidence View the Tirzepatide COA Current batch purity and identity testing, 2026-05-27. View the COA →

Compare Compare Semaglutide and Retatrutide Semaglutide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research